This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Topoisomerase I (TOP1)	<p>Studies in mice identified camptothecin analogs that could help treat solid tumors. In mouse models of non-small cell lung cancer (NSCLC), colon cancer and prostate cancer, the 14-aminocamptothecin TH-1338 decreased tumor size compared with the parent molecule. Ongoing studies include testing the activity of TH-1338 in CNS tumor xenograft models. Threshold Pharmaceuticals Inc.'s TH-1338 is in preclinical development for solid tumors. GlaxoSmithKline plc markets the camptothecin derivative Hycamtin topotecan for cervical cancer and small cell lung cancer. Pfizer Inc. markets the camptothecin derivative Camptosar irinotecan for colorectal cancer and NSCLC.</p> <p>SciBX 4(10); doi:10.1038/scibx.2011.280 Published online March 10, 2011</p>	Patent applications filed; available for licensing or partnering	<p>Duan, J.-X. <i>et al. J. Med. Chem.</i>; published online Feb. 22, 2011; doi:10.1021/jm101354u</p> <p>Contact: Jian-Xin Duan, Threshold Pharmaceuticals Inc., Redwood City, Calif. e-mail: jduan@thresholdpharm.com</p>